Kairos Pharma Outlines Strategic Acquisitions and Future Plans in Shareholder Update
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Businesswire
Image: Businesswire
Kairos Pharma Ltd. has provided a mid-year update for 2026, highlighting the acquisition of CL-741, a promising oncology asset, and outlining key clinical milestones. The company aims to advance its pipeline of cancer therapeutics while maintaining a low operational burn rate and leveraging strategic partnerships.
- 01Kairos Pharma is acquiring worldwide rights for CL-741, a Phase 1-ready c-MET kinase inhibitor targeting non-small cell lung cancer, with a market potential of $16.2 billion by 2026.
- 02The company plans to initiate a Phase 1 study with CL-741 and continue its Phase 2 trial of ENV-105 in prostate cancer, with key results expected by Q3 2026.
- 03Kairos has secured over $8 million in non-dilutive funding to support its clinical assets.
- 04The company is collaborating with Cedars-Sinai Medical Center and other institutions to enhance the reach of its therapies.
- 05CEO John Yu emphasized the commitment to generating sustainable shareholder returns through innovative cancer treatments.
Advertisement
In-Article Ad
Kairos Pharma Ltd., a clinical-stage biopharmaceutical company based in Los Angeles, has provided a comprehensive mid-year update for 2026 in a letter to shareholders from CEO John Yu, M.D. The company announced a strategic acquisition of CL-741, a clinical-stage oncology asset aimed at treating non-small cell lung cancer and esophageal and gastric cancers. This acquisition is expected to enhance Kairos's pipeline, which includes other promising candidates such as ENV-105 and KROS-201. The anticipated milestones for the remainder of 2026 include initiating a Phase 1 study for CL-741 and progressing existing trials for ENV-105, with results expected in Q3. Kairos Pharma has secured over $8 million in non-dilutive funding, allowing it to maintain a low operational burn rate while focusing on innovative cancer therapeutics. The company is also leveraging partnerships with leading medical institutions to broaden the impact of its therapies. As it moves forward, Kairos remains committed to delivering sustainable returns for its shareholders through its transformative therapeutic pipeline.
Advertisement
In-Article Ad
The advancements in Kairos Pharma's clinical trials could lead to new treatment options for patients with significant unmet medical needs in oncology.
Advertisement
In-Article Ad
Reader Poll
What do you think about Kairos Pharma's recent acquisition and plans?
Connecting to poll...
Read the original article
Visit the source for the complete story.